Literature DB >> 16635185

Guidelines for the use of palivizumab in infants and young children with congenital heart disease.

Makoto Nakazawa1, Tsutomu Saji, Fukiko Ichida, Kotaro Oyama, Kensuke Harada, Satoshi Kusuda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16635185     DOI： 10.1111/j.1442-200X.2006.02179.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN： 1328-8067            Impact factor:   1.524


× No keyword cloud information.
  6 in total

1.  A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.

Authors:  Yuji Orito; Naoyuki Otani; Yuki Matsumoto; Katsukuni Fujimoto; Nobuyuki Oshima; Brian M Maas; Luzelena Caro; Antonios O Aliprantis; Kara S Cox; Osamu Tokumaru; Masaaki Kodama; Hideo Kudo; Hiromitsu Imai; Naoto Uemura
Journal:  Clin Transl Sci       Date:  2022-05-17       Impact factor: 4.438

Review 2.  Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Authors:  Colleen Wegzyn; Lim Kai Toh; Gerard Notario; Sophie Biguenet; Kristina Unnebrink; Caroline Park; Doris Makari; Michael Norton
Journal:  Infect Dis Ther       Date:  2014-10-09

Review 3.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease.

Authors:  Paul A Checchia; Bosco Paes; Louis Bont; Paolo Manzoni; Eric A F Simões; Brigitte Fauroux; Josep Figueras-Aloy; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-01-09

Review 4.  Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.

Authors:  Silvia Vandini; Carlotta Biagi; Marcello Lanari
Journal:  Int J Mol Sci       Date:  2017-08-06       Impact factor: 5.923

5.  Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses.

Authors:  Deborah Friedman; Jon Fryzek; Xiaohui Jiang; Adam Bloomfield; Christopher S Ambrose; Pierre C Wong
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

6.  Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.

Authors:  Tomoko Kashiwagi; Yukiko Okada; Ken Nomoto
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.